India's pharmaceutical sector is a global powerhouse, ranking 3rd in volume and 11th in value.

A March 2026 report by the Press Information Bureau highlights India’s strong position as the “Pharmacy of the World,” ranking 3rd globally by volume and 11th by value. The pharmaceutical sector, valued at $60 billion in 2025, is projected to reach $130 billion by 2030, with a turnover of ₹4.72 lakh crore in FY25. India supplies 20% of global generics and 60% of vaccines to UNICEF. Strong regulation by Central Drugs Standard Control Organization and Indian Pharmacopoeia Commission supports growth, while the Biopharma SHAKTI initiative aims to boost biologics and biosimilars.

Key performance indicators: 

• Pharmaceutical exports totaled $30.5 billion in 2024-25, with 50% going to highly regulated markets such as the United States and the European Union. 
• Drugs and Pharmaceuticals received ₹13,193 crore in FDI for the first half of FY25-26, indicating strong international confidence. 
• PLI Success: As of September 2025, Production Linked Incentive schemes generated ₹40,890 crore in investment and saved imports of ₹3,591 crore in essential APIs and KSMs.
• Recently negotiated or proposed free trade agreements (FTAs) with the EU, the United Kingdom, and New Zealand will give Indian generics and medical devices with zero-duty access to hundreds of tariff lines. 
• As of March 2026, there are around 18,646 Jan Aushadhi Kendras in operating, saving citizens an estimated ₹8,000 crore every year on necessary medicines. 
• Medical device exports are expected to reach $4.1 billion in 2024-25, boosted by specialized medical device parks in Tamil Nadu and Uttar Pradesh.